Aetna announced plans on Thursday, September 27, to sell its Medicare prescription-drug business to WellCare Health Plans, a key step towards gaining regulator approval for its US$67.5 billion merger with CVS.
Although financial terms of the deal weren’t disclosed, in a securities filing, Aetna stated that the “purchase price is not material” to the company. The divestiture of the Medicare Part D to WellCare may help resolve objections to the CVS-Aetna deal from US antitrust regulators.
The company stated in the filing that, “Aetna believes the divestiture is a significant step toward completing the DOJ’s (Department of Justice) review.”
WellCare, a smaller health insurer that’s based in Tampa, Florida, has been using deals to fuel its expansion. The company completed a US$2.5 billion deal for the health insurer Meridian in early September, adding about 1.1 million insurance customers to its base of 4.4 million members.
Full Content: Reuters
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI